Contact
searchSearch
HMP Global
Login

Opioid Use Disorder Topic Center

Featured

Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
News
When Cost Sharing Increases, More Naloxone Prescriptions Go Unfilled
07/10/2024
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due...
07/10/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
four college students walking down a hall together
News
Adolescents and Young Adults Willing to Intervene During Overdose but Lack Naloxone Knowledge
06/11/2024
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of...
06/11/2024
Psych Congress Network
brain health
News
Rapid Procedural Approach Increases Opioid Treatment Initiation but Faces Resource Challenges
05/23/2024
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach...
05/23/2024
Psych Congress Network
News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
From Addiction Professional

News

Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
nursing home care
News
CYP2D6-Metabolized Opioids and Antidepressant Concomitant Use Increases Adverse Events in Nursing Home Residents
08/02/2024
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light on the potential risks associated with the simultaneous use of CYP2D6-metabolized opioids alongside CYP2D6-inhibiting (as opposed to CYP2D6-neutral) antidepressants among older nursing home residents.
Recent findings have shed light...
08/02/2024
Psych Congress Network
FDA building sign
News
FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment
07/23/2024
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.
The US Food and Drug...
07/23/2024
Psych Congress Network
News
When Cost Sharing Increases, More Naloxone Prescriptions Go Unfilled
07/10/2024
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due to insurance deductible resets at the beginning of the year, the percentage of naloxone prescriptions abandoned at US pharmacies increased, according to study results published in JAMA.
When cost sharing increased due...
07/10/2024
Psych Congress Network
four college students walking down a hall together
News
Adolescents and Young Adults Willing to Intervene During Overdose but Lack Naloxone Knowledge
06/11/2024
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of adolescents and young adults expressed a willingness to intervene in an opioid overdose event, only a small portion of those surveyed knew how to administer naloxone.
While a large majority of...
06/11/2024
Psych Congress Network
brain health
News
Rapid Procedural Approach Increases Opioid Treatment Initiation but Faces Resource Challenges
05/23/2024
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach to withdrawal management and initiation of injectable extended-release (XR)-naltrexone for opioid use disorder (OUD) helped more patients begin treatment but may be difficult to implement widely due to...
A rapid procedural (RP) approach...
05/23/2024
Psych Congress Network
News
One Year After ‘X Waiver’ Axing, Few New Patients Prescribed Meds for OUD
05/15/2024
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of buprenorphine prescribers increased following the elimination of the X waiver in January 2023, the total number of patients using the medication to manage opioid use disorder (OUD) “changed little.”
Though the number of...
05/15/2024
Psych Congress Network
rx summit
News
RX Summit Presenters Embrace Harm Reduction for Recovery-Ready Communities
04/09/2024
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for people with SUD demonstrate efficacy, but they continue to encounter social stigma and barriers, according to a poster presentation at the RX and Illicit Drug Summit.
Harm reduction services for...
04/09/2024
Psychiatry & Behavioral Health
Client at Pharmacy
News
Financial, Insurance Barriers May Interfere with Buprenorphine Dispensing at Pharmacy
04/02/2024
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance restrictions appear to deter some patients from filling buprenorphine prescriptions, according to a poster presented at the RX and Illicit Drug Summit.
Financial and insurance...
04/02/2024
Psychiatry & Behavioral Health
News
Vertex Prepares to Submit New Drug Application for Medication to Treat Acute Pain
02/01/2024

Tom Valentino

Tom Valentino
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive results in its Phase 3 program for its selective NaV1.8 inhibitor that was developed as an alternative to opioids for treating moderate-to-severe acute pain, Vertex Pharmaceuticals plans to submit its NDA application...
After announcing positive...
02/01/2024
Addiction Professional
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Adults Who Smoke Have More Chronic Pain, Use More Opioids
News
Adults Who Smoke Have More Chronic Pain, Use More Opioids
11/07/2024
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain, prescription opioid use, and severe work limitations rise with the number of cigarettes smoked daily, according to study results published in the American Journal of Preventive Medicine.
Rates of chronic pain,...
11/07/2024
Psych Congress Network
Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
depression stock photo
News
Add-on Lumateperone Eases MDD in Patients With Inadequate Antidepressant Response
11/04/2024
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the atypical antipsychotic lumateperone improved depressive symptoms and severity more than adjunctive placebo in patients with MDD with inadequate response to previous antidepressant therapy, according to a poster...
Adjunctive treatment with the...
11/04/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
A person steps onto a scale
News
Neuropsychiatric Side Effects Reported With CB1 Weight-Loss Drug
10/16/2024
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with statistically significant weight loss, but the drug was also linked with mild to moderate neuropsychiatric side effects.
Monlunabant was associated with...
10/16/2024
Psych Congress Network
Increase in Suicidality Associated With FDA Black Box Warning Implementation
News
Increase in Suicidality Associated With FDA Black Box Warning Implementation
10/11/2024
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on antidepressants from the FDA warning of increased risk of suicidality were associated with a decline in mental health treatment and an increase in suicide attempts and deaths in young people, according to a systematic...
Black box warnings on...
10/11/2024
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
News
Bright Light Therapy Effective for Depressive Disorders, May Improve Treatment Response Time
10/09/2024
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may be an effective adjunctive treatment for non-seasonal depressive disorders and improve response time for the initial treatment, according to results from a recent systematic review and meta-analysis published in...
Bright light therapy (BLT) may...
10/09/2024
Psych Congress Network

Quizzes

an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Expert Insights Quiz
LAIs and Telehealth Psychiatric Care
10/24/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
10/24/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Adult ADHD Diagnosis Rates
10/23/2024
Take the quiz to test your knowledge!
Take the quiz to test your knowledge!
Take the quiz to test your...
10/23/2024
Psych Congress Network
Jonathan Meyer
Quiz
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments?
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine...
10/23/2024
Psych Congress NP Institute
pop quiz
Quiz
Esketamine Dosing Schedule for Treatment-Resistant Depression
10/01/2024
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and maintenance phases of esketamine treatment, how frequently should the medication be administered to treat TRD? Take the quiz to test your psychopharmacology knowledge.
During the induction and...
10/01/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Telehealth Versus In-Person Psychiatric Care
09/19/2024
Do you know what the data from randomized control trials say?
Do you know what the data from randomized control trials say?
Do you know what the data from...
09/19/2024
Psych Congress Network
How many ADHD prescriptions are affected by the med shortage?
Quiz
How many ADHD prescriptions are affected by the med shortage?
09/17/2024
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent prescribing practices!
Take a quick poll on your recent...
09/17/2024
Psych Congress Network
Symptom Reduction in Bipolar Disorder Treatment
Expert Insights Quiz
Symptom Reduction in Bipolar Disorder Treatment
09/13/2024
Test your knowledge
Test your knowledge
Test your knowledge
09/13/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
CDC/AAP Treatment Guidelines for Pediatric ADHD
09/11/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
09/11/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
Quiz
Considerations When Prescribing Deutetrabenazine for Tardive Dyskinesia
09/10/2024
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to the test with this quiz!
Put your clinical knowledge to...
09/10/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use